IP Library Granted Patent US 10,933,115
Granted Patent B2
US 10,933,115 · App. 15/111,550 · Granted Mar 2, 2021

VISTA antagonist and methods of use

Inventors: Randolph J. Noelle (Plainfield, NH); Sabrina Ceeraz (Lebanon, NH); Isabelle Lemercier (Enfield, NH); Elizabeth Nowak (West Lebanon, NH); Janet Lines (London, GB); Li Wang (Norwich, VT); Mark Spaller (Lebanon, NH)
Assignees: THE TRUSTEES OF DARTMOUTH COLLEGE; KING'S GOLLEGE LONDON
A61K38/10A61K9/0019A61K39/0005A61K45/06C07K7/08C07K16/2827G01N33/566A61K38/00C07K2317/74C07K2317/76C07K2319/30Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,933,115
App. No.
15/111,550
Granted
Mar 2, 2021
Kind
B2
Abstract

The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.

Claims (6)

1. A method for blocking, inhibiting or neutralizing VISTA-mediated T cell suppression, comprising administering to a subject an effective amount of an isolated VISTA antagonist comprising a peptide which is identical to the amino acid sequence of SEQ ID NO:1 (Ser-Ser-Ala-Cys-Asp-Trp-Ile-Lys-Arg-Ser-Cys-His), or a conjugate, thereof.

2. A method for stimulating an immune response in a subject, comprising administering to the subject an effective amount of an isolated VISTA antagonist comprising a peptide which is identical to the amino acid sequence of SEQ ID NO:1 (Ser-Ser-Ala-Cys-Asp-Trp-Ile-Lys-Arg-Ser-Cys-His), or a conjugate thereof.

3. The method of claim 2 , wherein the subject has an infectious condition or cancer.

4. A method for enhancing anti-cancer or anti-tumor immunity, comprising administering to a subject an effective amount of an isolated VISTA antagonist comprising a peptide which is identical to the amino acid sequence of SEQ ID NO:1 (Ser-Ser-Ala-Cys-Asp-Trp-Ile-Lys-Arg-Ser-Cys-His), or conjugate thereof.

5. A method for treating or inhibiting tumor invasion and/or cancer metastasis, comprising administering to a subject an effective amount of an isolated VISTA antagonist comprising a peptide which is identical to the amino acid sequence of SEQ ID NO:1 (Ser-Ser-Ala-Cys-Asp-Trp-Ile-Lys-Arg-Ser-Cys-His), or a multimer or conjugate thereof.

6. A method according to claim 5 , further comprising the administration of another therapeutic agent, wherein said peptide and therapeutic may be separately or jointly administered, at the same or different times.

Assignments (1)
CONFIRMATORY LICENSE Recorded May 28, 2020
From: DARTMOUTH COLLEGE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 052780/0373 →
Continuity (3)
Continuation 14534793 · Nov 6, 2014
Provisional Application 61927061 · Jan 14, 2014
Related Publication 20160331803A1 · Nov 17, 2016